Uric Acid and Hypertension: An Update With Recommendations

Area of Science:

• Nephrology
• Cardiology
• Metabolic Disease

Background:

• The link between elevated serum urate and hypertension is debated.
• While Mendelian randomization suggests serum urate isn't causal for hypertension, it's linked to cardiac and vascular disease risks.
• Experimental data points to intracellular urate as a key factor in primary hypertension.

Purpose of the Study:

• To explore the role of intracellular urate in hypertension pathogenesis.
• To evaluate the potential benefits of lowering urate levels in hypertensive individuals.
• To investigate the connection between dietary factors, urate metabolism, and hypertension.

Main Methods:

• Review of existing literature on serum urate, hypertension, and cardiovascular disease.
• Analysis of pilot clinical trial data on urate-lowering interventions.
• Examination of evidence linking renin-angiotensin system (RAS) activation to hyperuricemia.
• Consideration of dietary impacts on intracellular urate production.

Main Results:

• Pilot trials suggest lowering serum urate benefits young, hypertensive patients with preserved kidney function.
• Evidence indicates hyperuricemia may activate the RAS, with potential benefits from RAS blockade.
• Dietary changes (reducing sugar, fructose, salt) may lower intracellular urate.

Conclusions:

• Intracellular urate, influenced by diet, may be crucial in primary hypertension.
• Further research is needed to clarify intra- and extracellular urate relationships.
• Large trials are required to confirm urate reduction benefits for hypertension and cardiometabolic disease.